Preparation, Characterization, and Inhibition of Hyaluronic Acid Oligosaccharides in Triple-Negative Breast Cancer

Han, Wenwei; Song, Lili; Wang, Yingdi; Lv, Yanna; Chen, Xiangyan; Zhao, Xia

doi:10.3390/biom9090436

Cited by 18 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the binding of HA oligomers to the CD44 and TLR4 receptors was MW-dependent. It was also found that the high binding energies of these short chains are accompanied by less cell viability . These results can explain the observed metabolic activity of MDA-MB-231 cells incubated with the HA products; however, each lyophilized product is a mixture of chains of different MWs, and the exact effect of each fragment cannot be studied under the current experimental conditions.…”

Section: Resultsmentioning

confidence: 96%

Interactions between Nitric Oxide and Hyaluronan Implicate the Migration of Breast Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Nitric oxide ( • NO) is one of the prominent free radicals, playing a pivotal role in breast cancer progression. Hyaluronic acid (HA) plays an essential role in neutralizing free radicals in tumor tissues. However, its interactions with nitric oxide have not been thoroughly investigated. Hence, this study attempts to understand the mechanism of these interactions and the different effects on the intracellular • NO levels and migration of breast cancer cells. The affinity of HA to scavenge • NO was investigated alongside the accompanying changes in specific physico-chemical properties and the further effects on the • NO-induced attachment and migration of the breast cancer cell lines, MDA-MB-231 and HCC1806. The reaction of the nitrogen dioxide radical, formed via • NO/O 2 interactions, with HA initiated a series of oxidative reactions, which, in the presence of • NO, induce the fragmentation of the polymeric chains. Furthermore, these interactions were found to hinder the NO-induced migration of cancer cells. However, the NO-induced HA modification/fragmentation was inhibited in the presence of hemin, a NO-scavenging compound. Collectively, these results help toward understanding the involvement of HA in the • NO-induced cell migration and suggest the possible modification of HA, used as one of the main materials in different biomedical applications.

show abstract

Section: Resultsmentioning

confidence: 96%

Interactions between Nitric Oxide and Hyaluronan Implicate the Migration of Breast Cancer Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…oHA is a degradation product of HA that is widely used in drug delivery systems because it is nontoxic, non-immunogenic, and biocompatible. It also exhibits tumor-targeting capability (Chen et al., 2017 ; Han et al., 2019 ).…”

Section: Resultsmentioning

confidence: 99%

Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer

Yang

He³

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Oxaliplatin resistance is one of the main causes of failed colorectal cancer treatment, followed by recurrence and metastasis. In this study, we found that colorectal cancer cells secrete a high level of hyaluronic acid (HA), which interacts with its receptor CD44v6 to mediate colorectal cancer resistance to chemotherapy. HA oligosaccharide (oHA) is a degradation product of HA. We found that it competitively binds to CD44v6, reversing the HA-CD44v6-mediated effect of HA on oxaliplatin resistance. In addition, oHA showed no toxicity or immunogenicity but exhibited good biocompatibility and tumortargeting capability. Therefore, we synthesized oHA-loaded oxaliplatin liposome nanoparticles (oHA-Lipid-Oxa) using a thin-film hydration method. The cytotoxicity of oHA-Lipid-Oxa was assessed in vitro using flow cytometry, which revealed greater lethality than oxaliplatin alone. Finally, we established a tumor-bearing nude mouse model and separately injected oHA-Lipid-Oxa, Lipid-Oxa, Oxa, oHA, and phosphate-buffered saline (PBS) into the tail vein to observe the antitumor effects of nanoparticles in vivo. The oHA-Lipid-Oxa group exhibited the highest tumor suppression rate, but the weight loss was not obvious. Hematoxylin and eosin staining showed greatest lymphocyte and macrophage infiltration in the oHA-Lipid-Oxa group. Moreover, oHA-Lipid-Oxa induced tumor cell apoptosis and necrosis most robustly compared with the other groups. We showed that oHA-Lipid-Oxa has excellent histocompatibility and CD44v6-targeting capabilities, thus greatly increasing the sensitivity to oxaliplatin and reducing adverse reactions. Accordingly, oHA-Lipid-Oxa has a broad potential for therapeutic application.

show abstract

“…In addition, sodium hyaluronate itself may have the potential to suppress cancer progression and metastasis (23)(24)(25)(26). It has highly metabolized in the lymphatic system, and migrates readily via lymphatic capillaries to regional lymph nodes following injection into breast tumor tissue (27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

New enzyme‑targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer

et al. 2021

View full text Add to dashboard Cite

Kochi oxydol radiation therapy for unresectable carcinomas II (KORTUC II) is currently the most widely used radiosensitizer in Japan. This sensitizer is a solution consisting of 0.83% sodium hyaluronate and 0.5% hydrogen peroxide. The mixture is injected intratumorally just before radiation therapy (RT) several times. KORTUC II has the effect of neutralizing antioxidant enzymes, while increasing the oxygen tension into the tumor tissue, and achieves marked local effects without notable adverse events. The present report describes cases in which KORTUC II was used to treat patients with locally advanced breast cancer (LABC) or recurrent breast cancer (LRBC). The present study included 30 patients with LABC (n=9) or LRBC (n=21) aimed at local control of tumors, who were followed up for ≥3 months after treatment. The irradiation dose and extent fields were determined by the attending physicians considering various patient factors, such as a performance status, prognosis and presence or absence of adjuvant therapy. The median irradiation dose was 60.4 Gy3.5 (43.6-76.1 Gy3.5) based on the calculation of equivalents of 2 Gy fractions, and the median total number of sensitizer injections was 5 ( 2-7 ) times. The median maximum tumor shrinkage was 97.0% and 15 patients (50%) were assessed to have achieved a clinical complete response. The proportion with loco-regional control at 1, 2 and 3 years was 100, 94.7 and 75.4%, respectively, and progression free survival after RT at 1 and 2 years was 59.0 and 24.1%, respectively. KORTUC II exhibited high rates of local tumor control for LABC and LRBC. KORTUC II is expected to be an inexpensive and promising RT method because it is safe and has an excellent radio-sensitizing effect.

show abstract

Preparation, Characterization, and Inhibition of Hyaluronic Acid Oligosaccharides in Triple-Negative Breast Cancer

Cited by 18 publications

References 47 publications

Interactions between Nitric Oxide and Hyaluronan Implicate the Migration of Breast Cancer Cells

Interactions between Nitric Oxide and Hyaluronan Implicate the Migration of Breast Cancer Cells

Novel hyaluronic acid oligosaccharide-loaded and CD44v6-targeting oxaliplatin nanoparticles for the treatment of colorectal cancer

New enzyme‑targeting radiosensitizer (KORTUC II) treatment for locally advanced or recurrent breast cancer

Contact Info

Product

Resources

About